Pluri Helping Placenta-Derived Collagen Company Scale Up Production in Europe
Resbiomed, a placental collagen materials manufacturer, is working on scaling up production for what appears regenerative ophthalmology in Europe.
Ophthalmology
BlueRock Cell Therapeutics Receives FDA Orphan Drug for its Ocular Stem Cell Therapy, OpCT-001
OpCT-001 is an iPSC-derived cell therapy for retinitis pigmentosa, and it's now entering clinical testing following Orphan Drug status.
Celularity to License its Amniotic Biologics to Opthalmic Startup DefEYE
Celularity and DefEYE’s agreement aims to accelerate the development and commercialization of advanced regenerative biologic solutions for ophthalmic care.
Neuroprotective Effects of SIRT1 Gene Therapy Protects Stem Cell-Derived Retinal Ganglion Cells from Oxidative Stress
Researchers are exploring whether SIRT1 gene therapy can protect human retinal cells from damage linked to optic neuropathies.
Stem Cell Trial: BlueRock Launches Study of iPSC-Derived Photoreceptor Cell Therapy for Inherited Retinal Diseases
The trial will test whether lab-grown photoreceptor cells can be safely transplanted to help people with inherited vision loss.
BlueRock Therapeutics Begins Phase 1/2a Trial of Stem Cell Therapy OpCT-001 for Retinal Diseases
The Bayer owned company just starting dosing patients with OpCT-001, an iPSC-derived cell therapy aiming to restore vision in inherited retinal diseases.
Bayer’s BlueRock Therapeutics receives FDA Fast Track Designation for its iPSC OpCT-001 for primary photoreceptor diseases
This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.
Luxa Biotechnology Reports Significant Results in Dry Age-Related Macular Degeneration Stem Cell Trial
Luxa Biotechnology LLC has shared clinical data from its Phase 1/2a trial of RPESC-RPE-4W, a retinal pigment epithelium cell therapy for dry age-related macular degeneration (dry AMD). On the trial page, they...
Study: Mass General successfully restores corneas with patients’ own stem cells
Link to the study on Nature The problem? Visual disturbances caused by a deficiency of limbal epithelial stem cells (LESCs) in one eye, known as unilateral limbal stem cell deficiency (USCD). It's...
Pandorum teams up with AGC Biologics to make stem cell exosomes for Ulcerative Corneal Blindness
Pandorum and AGC have teamed up to produce Pandorum's flagship exosome product Kuragenx, which they refer to as a 'liquid cornea'. Pandorum says that Kuragenx has demonstrated promising results in the preclinical...
